Physiologically-based pharmacokinetic (PBPK) modeling to predict disease effects on 5-flucytosine pharmacokinetics (PK) in the context of a switch from an immediate release (IR) to a sustained release (SR) formulation.

ConferenceInfectious diseasesPBPK-QSPSpecial populations